MultiSafepay joins Ant International’s Antom to Enhance Digital Payments Services for SMEs in Europe
1.7.2024 16:12:00 EEST | Business Wire | Press release
MultiSafepay (MSP), an Amsterdam-based payment service provider, and Antom global merchant payment services (Antom), a leading payment and digitization services provider under Ant International, announced today that MultiSafepay has become a wholly-owned subsidiary of Ant International and will integrate with Antom to promote convenient, secure and accessible payment solutions and digitalization services to businesses, especially small and medium-sized enterprises (SMEs) across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701540843/en/
Olaf Geurs, CEO of MultiSafepay (left) and Gary Liu, General Manager of Antom Global (right), in a ceremony. (Photo: Business Wire)
MultiSafepay now serves merchants with omnichannel payment services connecting over 40 international payment methods, including cards, e-wallets, Buy-Now, Pay-Laters, internet banking, and more. Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. In addition to flexible, secure and reliable payment options, Antom brings a suite of marketing and digitalization services to empower local and regional businesses with more growth opportunities.
Through this strategic partnership, MultiSafepay will leverage Antom’s cutting edge technology and digital capabilities to further expand its product offerings and SME merchant coverage in the region.
Since 1999, MultiSafepay has been a pioneer simplifying payment for SME businesses. It provides world-class payment solutions to over 18,000 SMEs, empowering them to concentrate on their business while MSP optimizes payment success rates, payment handling and processing combined with a personal approach.
Olaf Geurs, CEO of MultiSafepay said, “The past 25 years have been an incredible journey. Together with our amazing team, we've bootstrapped MultiSafepay into a leading full-service PSP in Europe, overcoming countless obstacles along the way. The entrepreneurial spirit never sleeps, which is why we're partnering with Antom to unlock even greater growth potential for MultiSafepay's products and services, attracting even more businesses to our ecosystem.”
Gary Liu, General Manager of Antom Global said, “We are thrilled to join hands with MultiSafepay, a trusted industry innovator and our long-term partner. SMEs are the pillar of regional and global prosperity. With digital innovations, we look forward to building together more secure, flexible and efficient payment solutions with cross-sector partners, for small businesses to thrive in a truly inclusive and sustainable global commerce ecosystem.”
About MultiSafepay
MultiSafepay is a leading Netherlands-based payment services provider using cutting-edge in-house-developed technology to help businesses of all sizes focus on growth and innovation. It offers European companies a simple, tailored payments ecosystem for online, in-person, and omnichannel solutions through a single platform and integration. MultiSafepay offers a personal approach to payments, optimizing payment success rates and reducing complexities to allow businesses and platforms to concentrate and drive their growth.
About Antom
Ant International’s Antom is a leading provider of payment and digitization services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitization services to help merchant in digital operations and to better engage with their customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701540843/en/
Contacts
Media contact:
Ant International
Fanny Wu
chen.wc@antgroup.com
Ant International
Joshua Way
joshua.way@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom